Michelle Laspaluto Sells 2,260 Shares of Chimerix, Inc. (NASDAQ:CMRX) Stock

Chimerix, Inc. (NASDAQ:CMRX) CFO Michelle Laspaluto sold 2,260 shares of the stock in a transaction that occurred on Thursday, February 13th. The shares were sold at an average price of $4.51, for a total transaction of $10,192.60. Following the sale, the chief financial officer now directly owns 172,977 shares in the company, valued at $780,126.27. This trade represents a 1.29 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink.

Michelle Laspaluto also recently made the following trade(s):

• On Thursday, January 30th, Michelle Laspaluto sold 1,015 shares of Chimerix stock. The shares were sold at an average price of $4.11, for a total transaction of $4,171.65.

Chimerix Stock Down 3.9 %

NASDAQ:CMRX opened at $4.38 on Friday. Chimerix, Inc. has a 12-month low of $0.75 and a 12-month high of $4.65. The firm has a market capitalization of $393.94 million, a price-to-earnings ratio of -4.66 and a beta of 0.35. The stock’s 50 day moving average price is $3.53 and its two-hundred day moving average price is $1.82.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently weighed in on CMRX shares. Wedbush reissued an “outperform” rating and set a $6.00 price target on shares of Chimerix in a research report on Tuesday, December 10th. HC Wainwright reissued a “buy” rating and issued a $11.00 price objective on shares of Chimerix in a research report on Monday, December 30th.

Institutional Investors Weigh In On Chimerix

Large investors have recently added to or reduced their stakes in the business. Assenagon Asset Management S.A. increased its holdings in shares of Chimerix by 154.8% in the fourth quarter. Assenagon Asset Management S.A. now owns 817,739 shares of the biopharmaceutical company’s stock valued at $2,846,000 after purchasing an additional 496,823 shares during the last quarter. Connor Clark & Lunn Investment Management Ltd. boosted its holdings in shares of Chimerix by 66.8% during the 3rd quarter. Connor Clark & Lunn Investment Management Ltd. now owns 344,712 shares of the biopharmaceutical company’s stock worth $321,000 after buying an additional 138,098 shares during the period. Peapod Lane Capital LLC bought a new stake in shares of Chimerix during the 4th quarter worth about $2,626,000. Stoneridge Investment Partners LLC grew its stake in Chimerix by 22.5% in the 4th quarter. Stoneridge Investment Partners LLC now owns 44,305 shares of the biopharmaceutical company’s stock valued at $154,000 after buying an additional 8,134 shares during the last quarter. Finally, Diadema Partners LP bought a new position in Chimerix in the 4th quarter valued at about $101,000. Institutional investors own 45.42% of the company’s stock.

Chimerix Company Profile

Chimerix, Inc, a biopharmaceutical company, develops medicines to improve and extend the lives of patients facing deadly diseases. Its pipeline products include ONC201 a program that is in Phase 3 clinical trial for treating patients with H3 K27M-mutant diffuse glioma, as well as in Phase 2 clinical trial for the treatment of rare neuroendocrine tumors; and ONC206, an imipridone, Dopamine Receptor D2 (DRD2) antagonist, and caseinolytic protease P (ClpP) agonist, which is in Phase 1 clinical trial for adult and pediatric patients with primary central nervous system tumors.